Cor Vasa 2022, 64(Suppl. 4):72-78

The year in cardiovascular medicine 2021: cardio-oncology

Joerg Teresa Alexander R.
1 Department of Cardiovascular Diseases, Mayo Clinic
2 Division of Cardiology, Cardiac Imaging and Cardio-Oncology Unit, La Paz University Hospital, IdiPAZ Research Institute
3 Cardio-Oncology Service, Royal Brompton Hospital and Imperial College

Received Date: 06 December 2021; Accepted Date: 16 December 2021; Publication date (electronic): 21 December 2021
Reproduced from: Herrmann J, López-Fernández T, Lyon AR. The year in cardiovascular medicine 2020: cardio-oncology. Eur Heart J. 2022 Jan 3;ehab891. https://doi.org/10.1093/eurheartj/ehab891, by permission of Oxford University Press on behalf of the European Society of Cardiology

Keywords: Cancer; Cardiovascular diseases; Cardio-oncology

Received: December 11, 2022; Accepted: December 11, 2022; Published: December 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Joerg Teresa Alexander R. The year in cardiovascular medicine 2021: cardio-oncology. Cor Vasa. 2022;64(Suppl. 4):72-78.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945-1960. Go to original source... Go to PubMed...
    2. Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:1504-1524. Go to original source... Go to PubMed...
    3. Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020;22:1966-1983. Go to original source... Go to PubMed...
    4. de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:2272-2289. Go to original source... Go to PubMed...
    5. Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, et al. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: an InternationalCardio-Oncology Society (ICOS) statement. CA Cancer J Clin 2020;70:480-504. Go to original source... Go to PubMed...
    6. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171-190. Go to original source... Go to PubMed...
    7. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;10:947-959. Go to original source... Go to PubMed...
    8. Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation 2021;144:e41-e55. Go to original source... Go to PubMed...
    9. Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (Breast and Prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med 2021;14:e000082. Go to original source... Go to PubMed...
    10. Mitchell JD, Cehic DA, Morgia M, Bergrom C, Toohey J, Guerrero PA, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-oncology Society. JACC CardioOncol 2021;3:360-380. Go to original source... Go to PubMed...
    11. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2021:ehab674. https://doi.org/10.1093/eurheartj/ehab674. Published online ahead of print. Go to original source... Go to PubMed...
    12. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020;41:1720-1729. Go to original source... Go to PubMed...
    13. Wang L, Wang F, Chen L, Geng Y, Yu S and Chen Z. Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study. Eur Heart J 2021;42:101-109. Go to original source... Go to PubMed...
    14. Grilz E, Posch F, Nopp S, Königsbrügge O, Lang IM, Klimek P, et al. Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. Eur Heart J 2021;42:2299-2307. Go to original source... Go to PubMed...
    15. Fu CH, Chen CH, Lin YH, Lee CW, Tsai LK, Tang SC, et al. Fibrin and platelet-rich composition in retrieved thrombi hallmarks stroke with active cancer. Stroke 2020;51:3723-3727. Go to original source... Go to PubMed...
    16. Guo W, Fan X, Lewis BR, Johnson MP, Rihal CS, Lerman A, et al. Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention. JACC Cardiovasc Interv 2021;14:1094-1105. Go to original source... Go to PubMed...
    17. Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;42:1019-1034. Go to original source... Go to PubMed...
    18. Salem JE, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, et al. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur Heart J 2021;42:3915-3928. Go to original source... Go to PubMed...
    19. Ye JZ, Hansen FB, Mills RW, Lundby A. Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability. JACC CardioOncol 2021;3:88-97. Go to original source... Go to PubMed...
    20. Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation 2020;142:2443-2455. Go to original source... Go to PubMed...
    21. Awan FT, Tong D, Zaha VG. Cardio-oncology: a win-win situation: how solving the mystery of an Ibrutinib off-target effect reveals new insights into atrial fibrillation mechanisms. Circulation 2020;142:2456-2458. https://doi.org/10.1161/CIRCULATIONAHA.120.052047. Published online ahead of print 21 December 2020. Go to original source... Go to PubMed...
    22. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother 2021;7: 312-320. Go to original source... Go to PubMed...
    23. Yun JP, Choi EK, Han KD, Park SH, Jung JH, Park SH, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol 2021;3:221-232. Go to original source... Go to PubMed...
    24. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J 2021:ehab745. Go to original source... Go to PubMed...
    25. Fradley MG, Ellenberg K, Alomar M, Swanson J, Kharod A, Nguyen ATH, et al. Patterns of anticoagulation use in patients with cancer with atrial fibrillation and/or atrial flutter. JACC CardioOncology 2020;2:747-754. Go to original source... Go to PubMed...
    26. Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, et al. Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. Eur J Prev Cardiol 2021;28:611-621. Go to original source... Go to PubMed...
    27. Rasmussen PV, Dalgaard F, Gislason GH, Brandes A, Johnsen SP, Grove EL, et al. Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation. Eur Heart J 2020:ehz964. Go to original source... Go to PubMed...
    28. Elbadawi A, Albaeni A, Elgendy IY, Ogunbayo GO, Jimenez E, Cornwell L, et al. Transcatheter versus surgical aortic valve replacement in patients with prior mediastinal radiation. JACC Cardiovasc Interv 2020;13:2658-2666. Go to original source... Go to PubMed...
    29. Nauffal V, Bay C, Shah PB, Sobieszczyk PS, Kaneko T, O'Gara P, et al. Short-term outcomes of transcatheter versus isolated surgical aortic valve replacement for mediastinal radiation-associated severe aortic stenosis. Circ Cardiovasc Interv 2021;14:e010009. Go to original source... Go to PubMed...
    30. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter compared with surgical aortic valve replacement in patients with previous chest-directed radiation therapy. JACC CardioOncol 2021;3:397-407. Go to original source... Go to PubMed...
    31. Kim SR, Kim EK, Cho J, Chang SA, Park SJ, Lee SC, et al. Effect of anti-inflammatory drugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll Cardiol 2020;76:1551-1561. Go to original source... Go to PubMed...
    32. Clayton ZS, Brunt VE, Hutton DA, VanDongen NS, D'Alessandro A, Reisz JA, et al. Doxorubicin-induced oxidative stress and endothelial dysfunction in conduit arteries is prevented by mitochondrial-specific antioxidant treatment. JACC CardioOncol 2020;2:475-488. Go to original source... Go to PubMed...
    33. Feher A, Boutagy NE, Stendahl JC, Hawley C, Guerrera N, Booth CJ, et al. Computed tomographic angiography assessment of epicardial coronary vasoreactivity for early detection of doxorubicin-induced cardiotoxicity. JACC CardioOncol 2020;2:207-219. Go to original source... Go to PubMed...
    34. Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, et al. Dual angiotensin receptor-neprilysin inhibition with sacubitril/valsartan attenuates systolic dysfunction in experimental doxorubicin-induced cardiotoxicity. JACC CardioOncol 2020;2:774-787. Go to original source... Go to PubMed...
    35. O'Brien CG, Ozen MO, Ikeda G, Vaskova E, Jung JH, Bayardo N, et al. Mitochondria-rich extracellular vesicles rescue patient-specific cardiomyocytes from doxorubicin injury: insights into the SENECA trial. JACC CardioOncol 2021;3:428-440. Go to original source... Go to PubMed...
    36. Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, et al. Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial. JACC CardioOncol 2020;2:581-595. Go to original source... Go to PubMed...
    37. Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc 2021;10:e018393. Go to original source... Go to PubMed...
    38. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 2021;77:392-401. Go to original source... Go to PubMed...
    39. Yu AF, Moskowitz CS, Chuy KL, Yang J, Dang CT, Liu JE, et al. Cardiotoxicity surveillance and risk of heart failure during HER2 targeted therapy. JACC CardioOncol 2020;2:166-175. Go to original source... Go to PubMed...
    40. D'Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 2021;42:1621-1631. Go to original source... Go to PubMed...
    41. Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020;41:1733-1743. Go to original source... Go to PubMed...
    42. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 2020;75:467-478. Go to original source... Go to PubMed...
    43. Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov 2021;11:614-625. Go to original source... Go to PubMed...
    44. Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 2021;ehab430. Go to original source... Go to PubMed...
    45. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020;142:2299-2311. Go to original source... Go to PubMed...
    46. Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, et al. Immune checkpoint inhibitor therapy aggravatesT cell-driven plaque inflammation in atherosclerosis. JACC CardioOncol 2020;2:599-610. Go to original source... Go to PubMed...
    47. Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol 2020;2: 193-203. Go to original source... Go to PubMed...
    48. Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78:1800-1813. Go to original source... Go to PubMed...
    49. Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med 2020;26:1452-1458. Go to original source... Go to PubMed...
    50. Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun 2021;12:2726. Go to original source... Go to PubMed...
    51. Grogan M, Lopez-Jimenez F, Cohen-Shelly M, Dispenzieri A, Attia ZI, Abou Ezzedine OF, et al. Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis. Mayo Clin Proc 2021;96:2768-2778. Go to original source... Go to PubMed...
    52. Schrutka L, Anner P, Agibetov A, Seirer B, Dusik F, Rettl R, et al. Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis. Heart 2021;42. https://doi.org/10.1136/heartjnl-2021-319846. Published online ahead of print. Go to original source... Go to PubMed...
    53. Alvarez-Cardona JA, Ray J, Carver J, Zaha V, Cheng R, Yang E, et al. Cardio-oncology education and training: JACC council perspectives. J Am Coll Cardiol 2020;76:2267-2281. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes